MAP3K12 and amyotrophic lateral sclerosis: Genetic manipulation or pharmacological inhibition of DLK, with compounds developed by Genentech, was reported to attenuate synaptic loss, neuronal degeneration and functional decline in models of AD, PD, and ALS in addition to acute neuronal injury models (Miller et al., 2009; Itoh et al., 2011; Pozniak et al., 2013; Watkins et al., 2013; Patel et al., 2015a, b, 2017; Le Pichon et al., 2017; Yin et al., 2017).